Previous study reported that PAX6 has oncogenic features and facilitates tumor progression (Jin et al. 2020) and FOXG1 has been reported to be elevated in the glioma (Chen et al. 2018) and dysfunction in the medulloblastoma (Adesina et al. 2007). Here, PAX6 is linked to central nervous system cancer.